Header Logo

Connection

SANJAY MATHEW to Anhedonia

Back to Details
This is a "connection" page, showing publications SANJAY MATHEW has written about Anhedonia.
SANJAY MATHEW
Connection Strength
1.329
Anhedonia
  1. Effects of KCNQ potassium channel modulation on ventral tegmental area activity and connectivity in individuals with depression and anhedonia. Mol Psychiatry. 2025 Aug; 30(8):3686-3694.
    View in: PubMed
    Score: 0.231
  2. Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS study. J Affect Disord. 2023 10 15; 339:584-592.
    View in: PubMed
    Score: 0.206
  3. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. Am J Psychiatry. 2021 05 01; 178(5):437-446.
    View in: PubMed
    Score: 0.174
  4. A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating ?-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 05; 26(5):760-768.
    View in: PubMed
    Score: 0.164
  5. Impulsivity and Suicidal Behavior. Curr Top Behav Neurosci. 2020; 47:179-195.
    View in: PubMed
    Score: 0.161
  6. The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. Nat Rev Drug Discov. 2018 12 28; 18(1):82-84.
    View in: PubMed
    Score: 0.150
  7. In vivo (1)H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder. Neurosci Lett. 2014 May 21; 569:74-9.
    View in: PubMed
    Score: 0.108
  8. Effects of the KCNQ (Kv7) Channel Opener Ezogabine on Resting-State Functional Connectivity of Striatal Brain Reward Regions, Depression, and Anhedonia in Major Depressive Disorder: Results From a Randomized Controlled Trial. Biol Psychiatry. 2025 Oct 01; 98(7):568-577.
    View in: PubMed
    Score: 0.058
  9. A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine. Int J Neuropsychopharmacol. 2022 10 25; 25(10):827-838.
    View in: PubMed
    Score: 0.049
  10. The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann N Y Acad Sci. 2015 May; 1345:47-58.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.